AMOP-H-OH (sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against human alpha4beta2-, alpha4beta4-, alpha3beta4*- and alpha1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for alpha4beta2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (alpha4)(3)(beta2)(2)-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for alpha4beta2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of alpha4beta2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on alpha4beta2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in alpha4beta2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.
AMOP-H-OH (n class="Chemical">sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against humanalpha4beta2-, alpha4beta4-, alpha3beta4*- and alpha1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for alpha4beta2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (alpha4)(3)(beta2)(2)-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for alpha4beta2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of alpha4beta2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on alpha4beta2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in alpha4beta2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.
Authors: A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London Journal: Mol Pharmacol Date: 2000-03 Impact factor: 4.436
Authors: J Brek Eaton; Jian-Hong Peng; Katherine M Schroeder; Andrew A George; John D Fryer; Chandra Krishnan; Lori Buhlman; Yen-Ping Kuo; Ortrud Steinlein; Ronald J Lukas Journal: Mol Pharmacol Date: 2003-12 Impact factor: 4.436
Authors: Amir H Rezvani; Olga Timofeeva; Hannah G Sexton; Damien DeCuir; Yingxian Xiao; Christopher J Gordon; Kenneth J Kellar; Edward D Levin Journal: Eur J Pharmacol Date: 2012-02-24 Impact factor: 4.432
Authors: Barbara J Caldarone; Daguang Wang; Neil E Paterson; Michael Manzano; Allison Fedolak; Katie Cavino; Mei Kwan; Taleen Hanania; Sheela K Chellappan; Alan P Kozikowski; Berend Olivier; Marina R Picciotto; Afshin Ghavami Journal: Psychopharmacology (Berl) Date: 2011-04-13 Impact factor: 4.530
Authors: Oluseye K Onajole; J Brek Eaton; Ronald J Lukas; Dani Brunner; Lucinda Thiede; Barbara J Caldarone; Alan P Kozikowski Journal: ACS Med Chem Lett Date: 2014-09-29 Impact factor: 4.345
Authors: G Patrick Hussmann; Jill R Turner; Ermelinda Lomazzo; Rashmi Venkatesh; Vanessa Cousins; Yingxian Xiao; Robert P Yasuda; Barry B Wolfe; David C Perry; Amir H Rezvani; Edward D Levin; Julie A Blendy; Kenneth J Kellar Journal: J Pharmacol Exp Ther Date: 2012-08-16 Impact factor: 4.030
Authors: J Brek Eaton; Linda M Lucero; Harrison Stratton; Yongchang Chang; John F Cooper; Jon M Lindstrom; Ronald J Lukas; Paul Whiteaker Journal: J Pharmacol Exp Ther Date: 2013-11-04 Impact factor: 4.030
Authors: G Patrick Hussmann; Kristen E DeDominicis; Jill R Turner; Robert P Yasuda; Jacquelyn Klehm; Patrick A Forcelli; Yingxian Xiao; Janell R Richardson; Niaz Sahibzada; Barry B Wolfe; Jon Lindstrom; Julie A Blendy; Kenneth J Kellar Journal: J Neurochem Date: 2014-02-07 Impact factor: 5.372